PDCD1 and hepatocellular carcinoma: In September 2017, nivolumab, a programmed cell death protein 1 (PD-1) antibody was firstly approved for the second-line treatment in patients with advanced HCC by the Food and Drug Administration (FDA) (El-Khoueiry et al., 2017).